

**MEMORANDUM**

DATE: July 16, 1992

TO: Talc Interested Parties

cc: SACX

FROM: Stephen D. Gettings, Ph.D., D.A.B.T.  
Director, Toxicology

SUBJ: ACTION ITEMS ARISING FROM JULY 15TH MEETING.

The following activities were agreed at the meeting on Wednesday:

- (1) Indicate (to CTFA) willingness to participate in funding of a background document assessing significance of the Harlow et al., article and a review of all pertinent information (animal/epidemiological data) on the question of any association between talc and ovarian cancer (see attached form).
- (2) Provide CTFA with names of possible consultants to perform (1) (see attached form).
- (3) Indicate (to CTFA) willingness to participate in funding of an assessment of the NTP inhalation study, with particular regard to the appropriateness of dose levels which result in overload of normal lung clearance mechanisms, and comparisons with other relevant inhalation studies (see attached form).
- (4) Provide CTFA with names of possible consultants to perform (3) (see attached form).

In addition, BSample to provide details of a prospective study to evaluate question of talc exposure and ovarian cancer.

**TALC INTERESTED PARTIES****AGENDA**

**CTFA**  
**Main Conference Room**  
**1101 17th Street, N.W., Suite 300**  
**Washington, DC 20036**

**July 15, 1992**  
**2:00 PM - 4:00 PM**

- I. **Opening Remarks**
  - A. **Review of CTFA Interested Party Procedures**
- II. **Perineal Exposure to Talc and Ovarian Cancer Risk**
  - A. **Review of paper by Harlow et al., (1992). Obstetrics & Gynecology, 80, 19-26.**
  - B. **Review of past studies and past industry response.**
  - C. **Media Interest/Response**
  - D. **Further Action**
- III. **NTP Technical Report on Toxicology in Carcinogenesis Studies on Talc.**
  - A. **Review of NTP Technical Report**
  - B. **NTP Peer Review**
  - C. **Regulatory Implications (Proposition 65, FDA)**
  - D. **Further Action**
- IV. **Any Other Business**
- V. **Adjourn**